The mechanism of sindilizumab combined with DOS regimen in the treatment of advanced gastric cancer based on KDM3A expression in cancer tissues
Objective To investigate the effect of sindilizumab combined with docetaxel+oxaliplatin+S-1(DOS)regimen on the expression of lysine demethylase 3A(KDM3A)in advanced gastric cancer tissues and its therapeutic mechanism.Methods A total of 104 patients with advanced gastric cancer admitted to our hospital from June 2019 to June 2021 were divided into the control group(n=52)and observation group(n=52).The DOS regimen was applied to both groups,and patients in the observation group were additionally treated with sindilizumab.Tumor markers,including carcinoembryonic antigen(CEA),carbohydrate antigen 724(CA724)and carbohydrate sugar antigen 125(CA125);tumor immune molecules before treatment(CD9,CD63,CD168,CD151);positive expressions of programmed death receptor-1(PD-1),PD-L1 and KDM3A;the Karnofsky functional status(KPS)score;adverse effects;survival and prognosis were compared between groups.Results After treatment,CEA,CA724 and CA125 in observation group were significantly lower compared with those of control group(P＜0.05).After treatment,CD168 and CD151 were significantly lower,while CD9 and CD63 were significantly higher in observation group compared with those of control group(P＜0.05).After treatment,the positive rates of PD-1,PD-L1 and KDM3A in the observation group were significantly lower compared with those of control group(P＜0.05).After treatment,KPS score of observation group was significantly higher compared with that of control group(P＜0.05).Compared with those of control group,the objective effective rate and disease control rate of observation group were significantly higher(P＜0.05).There was no significant difference in the incidence adverse events between the two groups(P＞0.05).Compared with those of the control group,the median survival time,12-month and 24-month survival rate of observation group were significantly longer(P＜0.05).Conclusion Sindilizumab combined with DOS regimen can inhibit the secretion of tumor markers in patients with advanced gastric cancer and prolong the lifespan by inhibiting the PD-1/PD-L1 signal transduction,improving body immunity,reducing KDM3A activity,and suppressing tumor cell proliferation and migration.
万方数据
维普
